Announcement List of NeuroSearch announcements in 2007 and in January - March 2008 In accordance with section 27a of Consolidated Act about Securities Trading etc., we hereby issue a complete list of NeuroSearch announcements in 2007 and in January - March 2008. All announcements are available under the IR section of our homepage www.neurosearch.com. -------------------------------------------------------------------------------- | Date | No | Headline | -------------------------------------------------------------------------------- | 03.01.2007 | 01-07 | NeuroSearch issues financial calendar for 2007 | -------------------------------------------------------------------------------- | 01.03.2007 | 02-07 | Notice concerning release date for the NeuroSearch | | | | financial statements 2006 | -------------------------------------------------------------------------------- | 05.03.2007 | 03-07 | NeuroSearch A/S - Financial statements 2006 | -------------------------------------------------------------------------------- | 07.03.2007 | 04-07 | NeuroSearch's license partner Abbott initiates | | | | clinical Phase II study with ABT-894 in Attention | | | | Deficit Hyperactivity Disorder (ADHD) | -------------------------------------------------------------------------------- | 08.03.2007 | 05-07 | List of NeuroSearch announcements in 2006 and in | | | | January - March 2007 | -------------------------------------------------------------------------------- | 13.03.2007 | 06-07 | NeuroSearch increases its share capital in | | | | connection with employees' exercise of warrants | -------------------------------------------------------------------------------- | 13.03.2007 | 07-07 | Report of transactions with shares and related | | | | securities of NeuroSearch by persons discharging | | | | managerial responsibilities and person/companies | | | | closely associated with these | -------------------------------------------------------------------------------- | 15.03.2007 | 08-07 | Report of transactions with shares and related | | | | securities of NeuroSearch by persons discharging | | | | managerial responsibilities and person/companies | | | | closely associated with these | -------------------------------------------------------------------------------- | 23.03.2007 | 09-07 | Report of transactions with shares and related | | | | securities of NeuroSearch by persons discharging | | | | managerial responsibilities and person/companies | | | | closely associated with these | -------------------------------------------------------------------------------- | 23.03.2007 | 10-07 | Report of transactions with shares and related | | | | securities of NeuroSearch by persons discharging | | | | managerial responsibilities and person/companies | | | | closely associated with these | -------------------------------------------------------------------------------- | 09.04.2007 | 11-07 | Notice convening annual general meeting in | | | | NeuroSearch A/S | -------------------------------------------------------------------------------- | 10.04.2007 | 12-07 | NeuroSearch's license partner Astellas initiates | | | | clinical Phase Ib study with ACR16 in patients with | | | | schizophrenia | -------------------------------------------------------------------------------- | 24.04.2007 | 13-07 | NeuroSearch and GlaxoSmithKline initiate second | | | | clinical Phase II study with NS2359 in depression | -------------------------------------------------------------------------------- | 25.04.2007 | 14-07 | NeuroSearch A/S - Q1 Report 2007 | -------------------------------------------------------------------------------- | 25.04.2007 | 15-07 | Report on ordinary general meeting held in | | | | NeuroSearch A/S | -------------------------------------------------------------------------------- | 26.04.2007 | 16-07 | Notice convening extraordinary general meeting in | | | | NeuroSearch A/S | -------------------------------------------------------------------------------- | 14.05.2007 | 17-07 | Report on extraordinary general meeting held in | | | | NeuroSearch A/S | -------------------------------------------------------------------------------- | 24.05.2007 | 18-07 | NeuroSearch's license partner Abbott initiates | | | | clinical Phase I study with ABT-107 | -------------------------------------------------------------------------------- | 01.06.2007 | 19-07 | Executive Order no. 226 of 15 March 2007 regarding | | | | issuers' obligations | -------------------------------------------------------------------------------- | 13.06.2007 | 20-07 | NeuroSearch updates on pipeline progress and status | -------------------------------------------------------------------------------- | 30.07.2007 | 21-07 | NeuroSearch's license partner Abbott initiates | | | | clinical Phase I study with ABT-560 | -------------------------------------------------------------------------------- | 22.08.2007 | 22-07 | NeuroSearch A/S - H1 Report 2007 | -------------------------------------------------------------------------------- | 07.09.2007 | 23-07 | NeuroSearch's license partner Abbott initiates | | | | clinical Phase II study with ABT-894 in neuropathic | | | | pain | -------------------------------------------------------------------------------- | 17.09.2007 | 24-07 | NeuroSearch announces breakthrough tesofensine | | | | results from clinical Phase IIb study in obesity | | | | (“TIPO-1”) | -------------------------------------------------------------------------------- | 01.10.2007 | 25-07 | NeuroSearch files Clinical Trial Application for | | | | the initiation of a clinical Phase III programme | | | | with ACR16 in Huntington's disease in Europe | -------------------------------------------------------------------------------- | 31.10.2007 | 26-07 | NeuroSearch today publishes an offering circular in | | | | connection with a rights issue of up to a maximum | | | | of 2,765,593 new shares with a nominal value of DKK | | | | 20 each at DKK 280 per share (the “Offering”) | -------------------------------------------------------------------------------- | 31.10.2007 | 27-07 | NeuroSearch announces revised financial calendar | | | | for 2007 and financial calendar for 2008 | -------------------------------------------------------------------------------- | 01.11.2007 | 28-07 | Indication from A.J. Aamund A/S and Asger Aamund | | | | regarding participation in NeuroSearch's rights | | | | issue | -------------------------------------------------------------------------------- | 27.11.2007 | 29-07 | NeuroSearch A/S completes preemptive rights issue | -------------------------------------------------------------------------------- | 28.11.2007 | 30-07 | NeuroSearch A/S - Q3 Report 2007 | -------------------------------------------------------------------------------- | 28.11.2007 | 31-07 | Notice convening extraordinary general meeting in | | | | NeuroSearch A/S | -------------------------------------------------------------------------------- | 01.12.2007 | 32-07 | NeuroSearch A/S' share capital and voting rights | -------------------------------------------------------------------------------- | 03.12.2007 | 33-07 | NeuroSearch issues new shares in connection with | | | | exercise of warrants | -------------------------------------------------------------------------------- | 03.12.2007 | 34-07 | NeuroSearch initiates clinical Phase I study with | | | | NSD-644 as a potential new pain treatment and | | | | receives milestone payment under the alliance with | | | | GlaxoSmithKline | -------------------------------------------------------------------------------- | 10.12.2007 | 35-07 | Report on extraordinary general meeting held in | | | | NeuroSearch A/S | -------------------------------------------------------------------------------- | 11.12.2007 | 36-07 | Notice convening extraordinary general meeting in | | | | NeuroSearch | -------------------------------------------------------------------------------- | 18.12.2007 | 37-07 | NeuroSearch initiates clinical Phase I study with | | | | ACR343 as a potential new treatment for Parkinson's | | | | disease | -------------------------------------------------------------------------------- | 21.12.2007 | 38-07 | Report on extraordinary general meeting held in | | | | NeuroSearch A/S | -------------------------------------------------------------------------------- | 28.12.2007 | 39-07 | NeuroSearch A/S' share capital and voting rights | -------------------------------------------------------------------------------- | 04.01.2008 | 01-08 | NeuroSearch announces the end of stabilisation | | | | period in connection with the rights issue, | | | | completed November 2007 | -------------------------------------------------------------------------------- | 17.01.2008 | 02-08 | NeuroSearch issues 185,755 new shares to the | | | | sellers of Carlsson Research AB as milestone | | | | payment relating to the start of ACR343 Phase I | | | | study | -------------------------------------------------------------------------------- | 22.01.2008 | 03-08 | NeuroSearch announces revised financial calendar | | | | for 2008 | -------------------------------------------------------------------------------- | 23.01.2008 | 04-08 | NeuroSearch has issued 185,755 new shares in a | | | | directed issuance to the sellers of Carlsson | | | | Research AB | -------------------------------------------------------------------------------- | 31.01.2008 | 05-08 | NeuroSearch A/S' share capital and voting rights | -------------------------------------------------------------------------------- | 03.03.2008 | 06-08 | NeuroSearch publishes positive and confirmatory | | | | results from TIPO-2, a clinical metabolic study | | | | with tesofensine for the treatment of obesity | -------------------------------------------------------------------------------- | 04.03.2008 | 07-08 | NeuroSearch A/S Financial statements 2007 | -------------------------------------------------------------------------------- Asger Aamund Chairman of the Board Contact person: Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications, telephone:+45 4460 8212 or 4017 5103 NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 12 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
List of NeuroSearch announcements in 2007 and in January - March 2008
| Source: NTG Nordic Transport Group A/S
Attachments
